Nucleic Acids For Future Gene Editing, Immunotherapy and
Epigenetic Sequence Modification
NATURE-ETN will leverage recent breakthrough discoveries in epigenetic manipulation, gene editing, small molecule DNA targeting, and rapid gene/transgene detection to extend the boundaries of molecular medicine and provide new tools for treating cancer and monogenetic diseases.
We offer 15 ESRs a unique PhD experience with multidisciplinary scientific, business and transferable skills training and the chance to build a pan-European network with leading scientists in Europe.
Our network is composed of ten beneficiaries and eight partner organisations from eight European countries, including:
- Ten leading research institutions;
- five cutting-edge SMEs;
- three multinationals.